Home | Regulatory Tracker | BPC-157 Legal Status
Is BPC-157 Legal? What Its Current FDA Category Actually Means
as of September 2026
By Stephen Kimball, 26+ years researching the health, wellness, supplement, and peptide industries
It’s not quite legal yet. At least in the way most people mean the question. As of September 2026, the FDA has not approved BPC-157 for any use. It is also not on FDA’s list of ingredients that pharmacies may use to make compounded medicines, which are custom medicines a pharmacist mixes for one patient. In July 2026 an FDA advisory panel voted to recommend adding it to that list. That vote is only advice, though, and nothing changes until the FDA writes and finalizes a new rule.
The rest of this page covers what the FDA’s current category for BPC-157 means, what the July vote did and didn’t change, and who is selling it today. It also covers what each of those sellers can and can’t promise you. For what BPC-157 is and what the research on it shows, see our BPC-157 encyclopedia entry.
What that actually means for you
Leaving the FDA’s safety-risk list is not the same as being cleared for use. A pharmacy can compound a drug from a raw ingredient only if that ingredient has an official quality standard, is part of an FDA-approved drug, or is on the FDA’s 503A bulks list — and BPC-157 meets none of the three as of September 2026. Its move out of Category 2 into the “nominated but withdrawn” table happened because the people who nominated it withdrew, not because the FDA dropped its safety concerns: the agency’s page still flags a possible immunogenicity risk (a risk the body’s immune system reacts against it) and says it “lacks sufficient information to know whether the drug would cause harm when administered to humans.” In short, BPC-157 is in limbo, not in the clear — federal rules give no pathway for a pharmacy to compound it right now.
Where it’s actually sold
You won’t find BPC-157 at a regular pharmacy. It’s mostly sold by “research use only” websites directly to consumers — no prescription, no medical oversight, and no guarantee the vial actually contains what the label claims. Telehealth and medspa clinics sell it too, sometimes with a short online consult, but a clinician’s involvement doesn’t change its unresolved federal status.
What happens next
On July 23, 2026, an FDA advisory panel voted 8–6, with one abstention, to recommend adding BPC-157 to the compounding list — reversing FDA staff’s own May 2026 recommendation against it. A favorable panel vote starts a process. It doesn’t finish one. Here is the process, and where BPC-157 is in it as of September 2026:
- The advisory panel recommends. Done on July 23, 2026. ← We are here.
- The FDA proposes a rule. The FDA publishes a proposal to add (or not add) BPC-157 to the compounding list. It is not bound by the panel’s vote. None has been published as of September 2026.
- Public comment. Anyone can comment on the proposal for a set period.
- Final rule. Only when the FDA finalizes a rule adding BPC-157 would pharmacies have a federal pathway to compound it.
The FDA has not announced a timeline, and we won’t guess at one. We update this page when the status changes. For analysis of the rulemaking step, see McDermott Will & Schulte’s summary of the two-day meeting.
Sources
FDA — Bulk Drug Substances Nominated for Compounding Under Section 503A (categorized list)
U.S. Food & Drug Administration
dated May 2026
FDA — Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026 (Docket FDA-2025-N-6895)
U.S. Food & Drug Administration
dated Jul 2026
Change log
September 2023
The FDA places BPC-157 in Category 2, its list of compounding ingredients with significant safety risks (APC copy of FDA’s Sept. 29, 2023 list).
April 2026
BPC-157 moves to the FDA’s “nominated but withdrawn” table after its nominators withdraw; the FDA’s safety concerns stay listed (FDA, current as of Apr 22, 2026).
May 2026
FDA staff recommend against adding BPC-157 to the compounding list (FDA briefing document); the May 14, 2026 categories list shows it in none of Categories 1, 2, or 3.
July 2026
The advisory panel votes 8–6, with one abstention, to recommend adding BPC-157, per ABC News.
Next
An FDA proposed rule. No date announced as of September 2026.
FAQs about BPC-157 legal status
Is BPC-157 FDA approved?
No. As of September 2026, BPC-157 is not FDA-approved for any use. “FDA-approved” means the agency has reviewed a specific drug product and decided that its benefits outweigh its risks for a specific condition. No company has put BPC-157 through that process. In its May 2026 briefing document, the FDA wrote that “there is no approved product containing BPC-157-related [ingredients] in any country at this time” (FDA briefing document). The same document says the FDA found only one registered human study of BPC-157 on ClinicalTrials.gov, the federal database where clinical trials are listed (NCT02637284). It was a small early-stage safety study in healthy volunteers in Mexico. No results have been posted, and the FDA couldn’t find a published paper from it.
What did the July 2026 advisory panel vote on BPC-157 change?
On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC, an outside panel of pharmacists, doctors, and consumer representatives who advise the FDA on compounding) reviewed BPC-157 for use in ulcerative colitis, a long-term inflammatory bowel disease (FDA meeting page). The panel voted 8 to 6, with one abstention, to recommend adding it to the compounding list, according to ABC News. As of September 2026, the FDA has not posted its own minutes or vote results for the meeting. The FDA’s own staff had recommended the opposite. The agency’s May 2026 briefing document recommended against adding BPC-157 to the list (FDA briefing document, §III). Its reasons, in plain terms: No clear chemical standard. The FDA said BPC-157 is “not well-characterized,” meaning there is no agreed definition of what a pure, correctly made batch should contain or what impurities to test for; No human safety data for how people actually use it. The FDA flagged the risk of immune reactions and gaps in testing for contamination, including bacteria and bacterial toxins; and thin evidence that it works for the condition under review. The FDA found “a lack of evidence to support the effectiveness” of BPC-157 for ulcerative colitis. The PCAC’s vote is advice. The FDA is not required to follow it. BPC-157’s status as of September 2026 is the same as it was before the meeting: not approved, and not on the compounding list.
Is BPC-157 illegal to buy or own?
BPC-157 is not a federally controlled substance. It does not appear on any of the Drug Enforcement Administration’s five drug schedules, the lists that make possessing a drug a crime (21 CFR Part 1308). Owning it is not treated the way owning a scheduled drug is.
“Not controlled” does not mean it is lawfully on the market. The FDA regulates the selling side. The agency has sent warning letters to companies selling products labeled as containing BPC-157, calling them unapproved new drugs, meaning drugs sold without the FDA review that federal law requires (FDA warning letter, June 2023; FDA warning letter, Oct. 2020). Those actions targeted sellers. We did not find FDA actions aimed at individual buyers. State laws can differ, and this page does not cover each state.
Where can people actually get BPC-157?
People can buy BPC-157 right now, but that is different from being safe or approved. As of September 2026, BPC-157 is not available as a prescription for an FDA-approved drug at a regular pharmacy; federal rules don’t let a pharmacy compound BPC-157, although some compounding pharmacies have been found advertising BPC-157 capsules, sprays, and injection kits (FDA briefing document); telehealth, medspa, and “longevity” clinics have also been found to be selling but the product carries the same unresolved federal status, and the FDA has not reviewed what’s in it; “Research use only” websites sell directly to consumers and are the most common source but it should be noted that “research use only” means the product is sold without a prescription, without medical oversight, and without FDA oversight of how it’s made so nothing guarantees its purity or its dose. The FDA’s briefing also notes that BPC-157 is marketed in the U.S. as a dietary supplement ingredient. The Defense Department’s Operation Supplement Safety (OPSS) program says BPC-157 “is not a dietary ingredient” and is an unapproved drug that can’t be lawfully sold over the counter (OPSS, April 2025). The FDA has sent warning letters treating BPC-157 products as unapproved drugs, as covered above.
Is BPC-157 banned for athletes and the military?
Yes. These rules are separate from the FDA’s, and the July vote changes none of them.
(WADA). BPC-157 is on WADA’s (World Anti-Doping Agency) Prohibited List under S0, “non-approved substances,” which are prohibited at all times, in and out of competition. The FDA’s own May 2026 briefing cites this listing (FDA briefing document). The 2025–26 NCAA Banned Substances list names BPC-157 under “Peptide hormones, growth factors, related substances and mimetics.” BPC-157 is also on the Department of Defense Prohibited Dietary Supplement Ingredients list (OPSS ingredient index; DoD prohibited list, last updated May 26, 2026). If you compete in drug-tested sport or serve in the military, BPC-157’s FDA status is beside the point for you. It is prohibited under these rules either way.